Literature DB >> 17982400

Integration of the anti-EGFR agent panitumumab into clinical practice in metastatic colorectal cancer.

Eric Van Cutsem1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17982400

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  2 in total

1.  A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).

Authors:  José María Viéitez; Manuel Valladares; Ignacio Peláez; Luis de Sande González; Jesús García-Foncillas; José Luis García-López; Carlos García-Girón; Margarita Reboredo; Humberto Bovio; Angel Jiménez Lacave
Journal:  Invest New Drugs       Date:  2010-03-06       Impact factor: 3.850

2.  ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs).

Authors:  Pramudita R Prasetyanti; Emily Capone; Daniela Barcaroli; Daniela D'Agostino; Silvia Volpe; Antonina Benfante; Sander van Hooff; Valentina Iacobelli; Cosmo Rossi; Stefano Iacobelli; Jan Paul Medema; Vincenzo De Laurenzi; Gianluca Sala
Journal:  Oncotarget       Date:  2015-07-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.